NanOptima is developing controlled release drug depots that reduce intraocular injections from 10-12 tim es, to as little as twice, per year
With these revolutionary depot treatments, NanOptima aims to radically improve the current standard of care for retinal diseases, maintaining steady intraocular drug concentrations- unlike standard injections.
Unmet Clinical Need
There is an urgent need for anti-VEGF treatments that can be injected much less frequently than current treatments.
Aging populations globally and rising incidence of diabetes contribute to continuing increases in age-related macular degeneration (AMD) (Visiongain 2019). AMD now affects 10% of people over 65 and 25% of people over 75 (INSERM 2014). AMD costs the UK approximately £1.6b/year (RNIB 2020).
Sight-saving anti-VEGF injections for wet-AMD in UK increased 215% between 2010/11 and 2014/15 (BMJ Open 2017); the NHS is unable to cope with demand for injections, with outpatient appointments rising 30% in recent years (Macular Society, 2016).
of people over 75
AMD injections increase d by
between 2010/11 and 2014/15
Age-related macular degeneration (AMD) is now a colossal healthcare challenge… Treatments as they currently stand are already at breaking point and arguably unsustainable in terms of cost to patients and healthcare systems
UK Director, Institute of Ophthalmology
NanOptima’s hydrogel drug depots are made from completely natural biocompatible and bioresorbable components, and are an innovative application of cutting-edge biomaterials research. The unique technology allows the depot properties to be tuned bespoke to the properties of the biopharmaceutical of choice for release, and to modulate release rate.